about
Systemic delivery of β-blockers via transdermal route for hypertensionAlginate microspheres of isoniazid for oral sustained drug delivery.A pharmacovigilance study of antihypertensive medicines at a South delhi hospital.Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan.Liposomal drug delivery systems: an update review.Microemulsions as a surrogate carrier for dermal drug delivery.A pharmacological appraisal of medicinal plants with antidiabetic potentialMedicine utilization review at a university teaching hospital in New Delhi.Particulate and vesicular drug carriers in the management of tuberculosis.Review of ocular drug delivery.Transdermal delivery of beta-blockers.Status of terpenes as skin penetration enhancers.Treatment of tuberculosis: use of active pharmaceuticals.Chemical penetration enhancers: a patent review.Status of fatty acids as skin penetration enhancers-a review.Drug utilization of oral hypoglycemic agents in a university teaching hospital in India.The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review.Contact lenses in ocular therapeutics.Herbal drugs for diabetic treatment: an updated review of patents.Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.A validated RP-HPLC method for simultaneous determination of propranolol and valsartan in bulk drug and gel formulation.Nanoparticles laden in situ gel for sustained ocular drug deliveryNanoemulsion components screening and selection: a technical note.An alternative in situ gel-formulation of levofloxacin eye drops for prolong ocular retentionStability-indicating assay of repaglinide in bulk and optimized nanoemulsion by validated high performance thin layer chromatography technique.Journal of pharmacy and bio allied sciences vol 4 issue 4.In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: a technical noteA three-way comparative study on the efficacy of twin sol to gel systems and marketed eye drops of pefloxacin mesylate.Hepatoprotective and behavioral effects of jigrine in galactosamine-induced hepatopathy in rats.Pharmacodynamics of a losartan transdermal system for the treatment of hypertension.Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system.Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention.Monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: in vitro characterisation.Transdermal drug delivery systems of a beta blocker: design, in vitro, and in vivo characterization.Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery.Free radical scavenging and hepatoprotective activity of jigrine against galactosamine induced hepatopathy in rats.The effect of penetration enhancers on permeation kinetics of nitrendipine in two different skin models.Transdermal therapeutic system of enalapril maleate using piperidine as penetration enhancer.Transdermal drug delivery of labetolol hydrochloride: system development, in vitro; ex vivo and in vivo characterization.
P50
Q26772083-1A612F5E-EE95-462A-8688-5E740B659D24Q33264018-7AADCC2D-F38A-45F0-8829-EF08B91A5EA0Q33834537-EAE665C1-4E64-4205-9A58-E428E2691BA7Q33942877-58FA759C-54F3-4A7A-8B13-F34AA3601134Q34708849-5A8F139A-04CD-422E-A3B8-E7290C624401Q34882750-0778CDB5-A990-4A94-98D6-139F16E6995BQ35770444-BD12688F-5660-4D5E-BEC9-4C0C7EB0860FQ36181823-B0EA0260-80BC-41FB-A1C7-556385DAA4CEQ36393464-4A29DF68-3CDF-4C11-9118-FE876884FF87Q36446989-FE81225D-D3CD-4A6E-8625-F507B9AB05F3Q36460864-E41D43C5-2B5D-4B68-B441-9317CDD84B6CQ37025631-87C8F047-058A-4CC3-B8ED-2A884B0E46D9Q37067323-1E884C8D-6DAA-40F5-8EFE-A44CB7E68D07Q37529814-ECB8B1DA-6B5C-46EF-8B93-8745B58BD2FDQ37551982-7997F3BE-9368-46B7-A688-0BFFC3BEC91BQ37787282-89766B73-9DA3-445E-83CE-CF85248AC4CEQ37854074-6C8A17D9-D8EC-4284-B53F-68F605B96C98Q37981409-87FC936D-B969-4F2F-A18D-96B4A098AF82Q37986878-CA3BF6F2-628C-4417-BC29-52F780637E28Q38234364-567DF7A4-29E6-4EEC-B9A8-E8C42D8E40B5Q39443684-45100054-8622-436B-B841-DD822B7E6ED4Q41448124-D84861A3-B765-4E59-917B-99628E25FB82Q41989363-E288C734-373B-487B-8023-CA703981A2A4Q42091502-BD57A34B-37A5-4FE1-8838-5A3C0A9D3B8AQ42157882-01923F21-2A53-4811-8F03-02C4BB5182B7Q42413113-EE04FF75-98A6-4DAB-BEB5-68BBD769739EQ42564163-2E07A339-FF6F-4CE2-87E6-C00300791B61Q42633996-49DF567B-7804-40AA-BB8A-F598E1423094Q42964530-B011CE26-E8D0-42F0-B905-E7CD332F0659Q43141756-D97DF7E9-C8D5-45A2-B1F6-D4C006A3FBA4Q43254741-06782ADD-F471-4B6D-B9DA-6CB4A7E9E88AQ43259069-C9DDCB77-CD1B-4681-AA31-014CBFB91D7AQ43940458-3186CCEA-64FA-4739-A823-EAB54DF98618Q44111296-4C0AAFBC-EF70-479F-9196-437D92173566Q44914843-FF77265C-64BA-485D-A81D-82910368F09AQ45146497-9FF7A749-6F9F-4421-B398-1C6D900CEEE8Q45290591-A47A0E2E-C043-419A-8B61-0D5FB6546790Q46403196-8E9D0E77-78CE-4DD5-8929-0B7229B04EBBQ46660555-6E28225B-741C-4386-A049-36479938F3E3Q46817814-C34A027C-29DA-4417-8EBF-D41AA3C12187
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mohd Aqil
@ast
Mohd Aqil
@en
Mohd Aqil
@es
Mohd Aqil
@nl
Mohd Aqil
@sl
type
label
Mohd Aqil
@ast
Mohd Aqil
@en
Mohd Aqil
@es
Mohd Aqil
@nl
Mohd Aqil
@sl
altLabel
Mohammed Aqil
@en
prefLabel
Mohd Aqil
@ast
Mohd Aqil
@en
Mohd Aqil
@es
Mohd Aqil
@nl
Mohd Aqil
@sl
P106
P1153
35551158100
P21
P31
P496
0000-0001-6797-3104
P569
2000-01-01T00:00:00Z